Drug intelligence / Profile preview

PEG-Au@SiO2-SNO

Development stage: Preclinical
Lead developer: Nanjing Forestry University
Modality: Nanoparticles → Drug Delivery Systems
Administration: Intravenous

Overview

PEG-Au@SiO2-SNO is an experimental PEGylated gold nanorod@mesoporous-silica nanocomposite bearing **S-nitrosothiol nitric-oxide donor groups**. Near-infrared irradiation produces photothermal heating from the gold nanorod core, which accelerates nitric oxide release from the S-nitrosothiol groups and enables combined mild photothermal and nitric-oxide gas therapy. It was reported in preclinical MCF-7 breast-cancer models; the published broader treatment formulation additionally loaded the HSP70 inhibitor 2-phenylethynesulfonamide, but PES is not a component of PEG-Au@SiO2-SNO itself. ([x-mol.com](https://www.x-mol.com/paper/1228436772609871872))

Other names: PEG-Au@SiO2-SNO

Beyond the preview

Go deeper on PEG-Au@SiO2-SNO.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PEG-Au@SiO2-SNO.

Explore the full profile